CG
AUPH icon

Caprock Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Caprock Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$756K Buy
44,542
+12,950
+41% +$207K 0.01% 716
2026
Q1 		$468K Buy
31,592
+4,265
+16% +$62.3K 0.01% 773
2025
Q4 		$436K Buy
+27,327
New +$387K 0.01% 873

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caprock Group's AUPH Position: Q2 2026 in Review

Caprock Group increased its Aurinia Pharmaceuticals (AUPH) stake by 41% in Q2 2026, buying an estimated $207K and bringing the position to 44,542 shares worth $756K. The position accounts for 0.01% of the portfolio, ranked #716.

Caprock Group first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Caprock Group held 44,542 shares of Aurinia Pharmaceuticals worth $756K as of Q2 2026.
  • Caprock Group bought 12,950 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Aurinia Pharmaceuticals made up 0.01% of Caprock Group's portfolio in Q2 2026, its #716 holding.
  • Caprock Group first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.